The biggest flaw in the Obama approach to bundling is that the administration is lumping the doctors’ services along with the cost of the technology that physicians use to treat patients and paying for both in the same “bundled” payment. That means that if a physician chooses to use newer but pricier drugs to treat a cancer, for example, then the cost of the medicines will come out of the doctors’ bottom line.
One year into the Obama Administration’s first test of a bundled payment arrangement—put in place for paying providers to treat dialysis patients—we are already seeing signals that this financial conflict may be leading to degradation in patient care. Over the first year that the dialysis bundle was in place, parathyroid hormone levels in the dialysis patient community rose 25%. This is a clinical parameter that is closely followed in dialysis patients for monitoring the effects of their kidney dysfunction. The rising levels may be an early indication that doctors are underutilizing certain key drugs in caring for these patients.
via The Enterprise Blog.
Posted by Chris Conover 